© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 13, 979-989,
July 4, 2001
© 2001 Oxford University Press
SPECIAL ARTICLE |
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1–3, 2000
National Institutes of Health Consensus Development Panel*
Correspondence to: John A. Bowersox, Communications Specialist, Office of Medical Applications of Research, National Institutes of Health, Bldg. 31, Rm. 1B03, Bethesda, MD 20892 (e-mail bowersoj{at}od.nih.gov).
Objective: Our goal was to provide health-care providers, patients, and the general public with an assessment of currently available data regarding the use of adjuvant therapy for breast cancer. Participants: The participants included a non-Federal, non-advocate, 14-member panel representing the fields of oncology, radiology, surgery, pathology, statistics, public health, and health policy as well as patient representatives. In addition, 30 experts in medical oncology, radiation oncology, biostatistics, epidemiology, surgical oncology, and clinical trials presented data to the panel and to a conference audience of 1000. Evidence: The literature was searched with the use of MEDLINETM for January 1995 through July 2000, and an extensive bibliography of 2230 references was provided to the panel. Experts prepared abstracts for their conference presentations with relevant citations from the literature. Evidence from randomized clinical trials and evidence from prospective studies were given precedence over clinical anecdotal experience. Consensus Process: The panel, answering predefined questions, developed its conclusions based on the evidence presented in open forum and the scientific literature. The panel composed a draft statement, which was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately after its release at the conference and was updated with the panel's final revisions. The statement is available at http://consensus.nih.gov. Conclusions: The panel concludes that decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy should be offered only to women whose tumors express hormone receptor protein. Because adjuvant polychemotherapy improves survival, it should be recommended to the majority of women with localized breast cancer regardless of lymph node, menopausal, or hormone receptor status. The inclusion of anthracyclines in adjuvant chemotherapy regimens produces a small but statistically significant improvement in survival over non-anthracycline-containing regimens. Available data are currently inconclusive regarding the use of taxanes in adjuvant treatment of lymph node-positive breast cancer. The use of adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer and of taxanes in lymph node-negative breast cancer should be restricted to randomized trials. Ongoing studies evaluating these treatment strategies should be supported to determine if such strategies have a role in adjuvant treatment. Studies to date have included few patients older than 70 years. There is a critical need for trials to evaluate the role of adjuvant chemotherapy in these women. There is evidence that women with a high risk of locoregional tumor recurrence after mastectomy benefit from postoperative radiotherapy. This high-risk group includes women with four or more positive lymph nodes or an advanced primary cancer. Currently, the role of postmastectomy radiotherapy for patients with one to three positive lymph nodes remains uncertain and should be tested in a randomized controlled trial. Individual patients differ in the importance they place on the risks and benefits of adjuvant treatments. Quality of life needs to be evaluated in selected randomized clinical trials to examine the impact of the major acute and long-term side effects of adjuvant treatments, particularly premature menopause, weight gain, mild memory loss, and fatigue. Methods to support shared decision-making between patients and their physicians have been successful in trials; they need to be tailored for diverse populations and should be tested for broader dissemination.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. S. Wittner, D. C. Sgroi, P. D. Ryan, T. J. Bruinsma, A. M. Glas, A. Male, S. Dahiya, K. Habin, R. Bernards, D. A. Haber, et al. Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort Clin. Cancer Res., May 15, 2008; 14(10): 2988 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Haffty, T. A. Buchholz, and B. McCormick Should Intensity-Modulated Radiation Therapy Be the Standard of Care in the Conservatively Managed Breast Cancer Patient? J. Clin. Oncol., May 1, 2008; 26(13): 2072 - 2074. [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Becker, R. E. Ellsworth, B. Deyarmin, H. L. Patney, R. M. Jordan, J. A. Hooke, C. D. Shriver, and D. L. Ellsworth The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer Ann. Surg. Oncol., April 1, 2008; 15(4): 1056 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Mamounas Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings Ann. Surg. Oncol., March 1, 2008; 15(3): 691 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cardoso, L. Van't Veer, E. Rutgers, S. Loi, S. Mook, and M. J. Piccart-Gebhart Clinical Application of the 70-Gene Profile: The MINDACT Trial J. Clin. Oncol., February 10, 2008; 26(5): 729 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz and E. E. Hahn Implementing a Survivorship Care Plan for Patients With Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 759 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Collins, J. D. Marotti, H. J. Baer, and R. M. Tamimi Comparison of Estrogen Receptor Results From Pathology Reports With Results From Central Laboratory Testing J Natl Cancer Inst, February 6, 2008; 100(3): 218 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-P. P. Tran and J. L. Grabinski Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56. [Abstract] [PDF]
|
|
|
|
 |
|
 M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study Ann. Onc., December 1, 2007; 18(12): 1976 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Heaphy, K. B. Baumgartner, M. Bisoffi, R. N. Baumgartner, and J. K. Griffith Telomere DNA Content Predicts Breast Cancer Free Survival Interval Clin. Cancer Res., December 1, 2007; 13(23): 7037 - 7043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kennedy, A. K. Stewart, K. Y. Bilimoria, L. Patel-Parekh, S. F. Sener, and D. P. Winchester Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients Ann. Surg. Oncol., October 1, 2007; 14(10): 2918 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Gentilini, E Botteri, N Rotmensz, M Intra, G Gatti, L Silva, N Peradze, R. Sahium, L. Gil, A Luini, et al. Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution Ann. Onc., August 1, 2007; 18(8): 1342 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Cronin-Fenton, L. A. Ries, L. X. Clegg, and B. K. Edwards Rising Incidence Rates of Breast Carcinoma With Micrometastatic Lymph Node Involvement J Natl Cancer Inst, July 4, 2007; 99(13): 1044 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Davis, C. Harris, L. Tang, P. Doherty, P. Hraber, Y. Sakai, T. Bocklage, K. Doeden, B. Hall, J. Alsobrook, et al. Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma J. Mol. Diagn., July 1, 2007; 9(3): 327 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Gondos, B Holleczek, V Arndt, C Stegmaier, H Ziegler, and H Brenner Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann. Onc., July 1, 2007; 18(7): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Desmedt, F. Piette, S. Loi, Y. Wang, F. Lallemand, B. Haibe-Kains, G. Viale, M. Delorenzi, Y. Zhang, M. S. d'Assignies, et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series Clin. Cancer Res., June 1, 2007; 13(11): 3207 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ross, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes Clin. Cancer Res., May 15, 2007; 13(10): 2831 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ma, Y. Qian, L. Wei, J. Abraham, X. Shi, V. Castranova, E. J. Harner, D. C. Flynn, and L. Guo Population-Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling Clin. Cancer Res., April 1, 2007; 13(7): 2014 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Climent, P. Dimitrow, J. Fridlyand, J. Palacios, R. Siebert, D. G. Albertson, J. W. Gray, D. Pinkel, A. Lluch, and J. A. Martinez-Climent Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer Cancer Res., January 15, 2007; 67(2): 818 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Roche, P. Fumoleau, M. Spielmann, J.-L. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulie, F. Eichler, et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial J. Clin. Oncol., December 20, 2006; 24(36): 5664 - 5671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K Gruvberger-Saal, H. E Cunliffe, K. M Carr, and I. A Hedenfalk Microarrays in breast cancer research and clinical practice - the future lies ahead Endocr. Relat. Cancer, December 1, 2006; 13(4): 1017 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buyse, S. Loi, L. van't Veer, G. Viale, M. Delorenzi, A. M. Glas, M. Saghatchian d'Assignies, J. Bergh, R. Lidereau, P. Ellis, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst, September 6, 2006; 98(17): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., August 10, 2006; 24(23): 3726 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Norwood, T. J. Moss, N. V. Margaryan, S. L. Cook, L. Wright, E. A. Seftor, M. J. C. Hendrix, D. A. Kirschmann, and L. L. Wallrath A Requirement for Dimerization of HP1Hs{alpha} in Suppression of Breast Cancer Invasion J. Biol. Chem., July 7, 2006; 281(27): 18668 - 18676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, S. M. Tarr, M. C.U. Cheang, B. J. Yoder, G. T. Budd, T. O. Nielsen, D. G. Hicks, et al. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3039 - 3047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature J. Clin. Oncol., May 1, 2006; 24(13): 2113 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sonmezer and K. Oktay Fertility preservation in young women undergoing breast cancer therapy. Oncologist, May 1, 2006; 11(5): 422 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Schnitt Estrogen Receptor Testing of Breast Cancer in Current Clinical Practice: What's the Question? J. Clin. Oncol., April 20, 2006; 24(12): 1797 - 1799. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Callagy, P. D. Pharoah, S. E. Pinder, F. D. Hsu, T. O. Nielsen, J. Ragaz, I. O. Ellis, D. Huntsman, and C. Caldas Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index Clin. Cancer Res., April 15, 2006; 12(8): 2468 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Foekens, D. Atkins, Y. Zhang, F. C.G.J. Sweep, N. Harbeck, A. Paradiso, T. Cufer, A. M. Sieuwerts, D. Talantov, P. N. Span, et al. Multicenter Validation of a Gene Expression-Based Prognostic Signature in Lymph Node-Negative Primary Breast Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1665 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Reis-Filho, C Westbury, and J-Y Pierga The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Linke, T. M. Bremer, C. D. Herold, G. Sauter, and C. Diamond A Multimarker Model to Predict Outcome in Tamoxifen-Treated Breast Cancer Patients Clin. Cancer Res., February 15, 2006; 12(4): 1175 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cobleigh, B. Tabesh, P. Bitterman, J. Baker, M. Cronin, M.-L. Liu, R. Borchik, J.-M. Mosquera, M. G. Walker, and S. Shak Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes Clin. Cancer Res., December 15, 2005; 11(24): 8623 - 8631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. L. Du, D. V. Jones, and D. Zhang Effectiveness of Adjuvant Chemotherapy for Node-Positive Operable Breast Cancer in Older Women J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2005; 60(9): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ryan, D. B. Kopans, and D. C. Sgroi Case 24-2005 - A 58-Year-Old Woman with Early-Stage Estrogen-Receptor-Positive Breast Cancer N. Engl. J. Med., August 11, 2005; 353(6): 617 - 622. [Full Text] [PDF]
|
|
|
|
|
|
F. Boccardo, A. Rubagotti, M. Puntoni, P. Guglielmini, D. Amoroso, A. Fini, G. Paladini, M. Mesiti, D. Romeo, M. Rinaldini, et al. Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial J. Clin. Oncol., August 1, 2005; 23(22): 5138 - 5147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Pierce The Use of Radiotherapy After Mastectomy: A Review of the Literature J. Clin. Oncol., March 10, 2005; 23(8): 1706 - 1717. [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Chang, D. S. A. Nuyten, J. B. Sneddon, T. Hastie, R. Tibshirani, T. Sorlie, H. Dai, Y. D. He, L. J. van't Veer, H. Bartelink, et al. From The Cover: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival PNAS, March 8, 2005; 102(10): 3738 - 3743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy Predictive Markers in Breast and Other Cancers: A Review Clin. Chem., March 1, 2005; 51(3): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jacquemier, C. Ginestier, J. Rougemont, V.-J. Bardou, E. Charafe-Jauffret, J. Geneix, J. Adelaide, A. Koki, G. Houvenaeghel, J. Hassoun, et al. Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis Cancer Res., February 1, 2005; 65(3): 767 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bonadonna, A. Moliterni, M. Zambetti, M. G. Daidone, S. Pilotti, L. Gianni, and P. Valagussa 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study BMJ, January 29, 2005; 330(7485): 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Kamath, A. D. Thor, C. Wang, S. M. Edgerton, A. Slusarczyk, D.J. Leary, J. Wang, E.L. Wiley, B. Jovanovic, Q. Wu, et al. Perinucleolar Compartment Prevalence Has an Independent Prognostic Value for Breast Cancer Cancer Res., January 1, 2005; 65(1): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F. L. Baehner, M. G. Walker, D. Watson, T. Park, et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer N. Engl. J. Med., December 30, 2004; 351(27): 2817 - 2826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fargeot, J. Bonneterre, H. Roche, A. Lortholary, M. Campone, I. Van Praagh, A. Monnier, M. Namer, S. Schraub, J.-C. Barats, et al. Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial J. Clin. Oncol., December 1, 2004; 22(23): 4674 - 4682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Erman, H. Abali, B. Oran, I. C. Haznedaroglu, H. Canpinar, S. Kirazli, and I. Celik Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann. Onc., November 1, 2004; 15(11): 1622 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Silliman Crossing the Quality Chasm in Breast Cancer Care J. Clin. Oncol., September 15, 2004; 22(18): 3654 - 3656. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. O'Regan Do Tumors Detected by Mammography Screening Have a Favorable Prognosis? JAMA, September 1, 2004; 292(9): 1062 - 1063. [Full Text] [PDF]
|
|
|
|
|
|
C. Schairer, P. J. Mink, L. Carroll, and S. S. Devesa Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients J Natl Cancer Inst, September 1, 2004; 96(17): 1311 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli, and R. A. Silliman Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor--Positive Breast Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3309 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Denkert, W. Weichert, K.-J. Winzer, B.-M. Muller, A. Noske, S. Niesporek, G. Kristiansen, H. Guski, M. Dietel, and S. Hauptmann Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma Clin. Cancer Res., August 15, 2004; 10(16): 5580 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cristofanilli and G. N. Hortobagyi Breast Cancer Highlights: Key Findings from the San Antonio Breast Cancer Symposium: A U.S. Perspective Oncologist, July 1, 2004; 9(4): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Chia, C. H. Speers, C. J. Bryce, M. M. Hayes, and I. A. Olivotto Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion-Negative Early Breast Cancers Without Adjuvant Systemic Therapies J. Clin. Oncol., May 1, 2004; 22(9): 1630 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Truong, I. A. Olivotto, T. J. Whelan, and M. Levine Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy Can. Med. Assoc. J., April 13, 2004; 170(8): 1263 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
|